Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIPshort

Cancer Research

Volumn 61, Issue 19, 2001, Pages 7148-7154

  Chatterjee, Devasis ^a   Schmitz, Ingo ^b   Krueger, Andreas ^b   Yeung, Kam ^a   Kirchhoff, Sabine ^b   Krammer, Peter H ^b   Peter, Marcus E ^c   Wyche, James H ^a   Pantazis, Panayotis ^a  

^a BROWN UNIVERSITY   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CELL PROTEIN; DNA; DNA TOPOISOMERASE; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; LIGAND; NEUTRALIZING ANTIBODY; RUBITECAN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; CORRELATION FUNCTION; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; EXPRESSION VECTOR; HUMAN; HUMAN CELL; OLIGOMERIZATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN SYNTHESIS;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CASPASES; DOWN-REGULATION; ENZYME ACTIVATION; ENZYME PRECURSORS; FAS LIGAND PROTEIN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE GLYCOPROTEINS; PROSTATIC NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0035476242     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitrocamptothecin
2. Mechanism of cellular resistance to sequential topoisomerase poisoning
3. Protein-linked, DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I
4. Mechanism of action of camptothecin
5. Design of topoisomerase inhibitors to overcome MDR1-mediated drug resistance
6. Preclinical studies of water-insoluble camptothecin congeners: Cytotoxicity, development of resistance, and combination treatments
7. The water-insoluble camptothecin analogues: Promising drugs for the effective treatment of haematological malignancies
8. 9-Nitrocamptothecin
9. 1 arrest followed by necrotic cell death
10. Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase-7
11. Mammalian cell death proteases: A family of highly conserved aspartate specific cysteine proteases
12. Caspases: The executioners of apoptosis
13. Caspases: Intracellular signaling by proteolysis
14. Signal transduction pathways that regulate cell survival and cell death
15. Caspases: The proteases of the apoptotic pathway
16. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner
17. Apoptosis by death factor
18. Apoptosis signaling by death receptors
19. Monoclonal antibody-mediated tumor regression by induction of apoptosis
20. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
21. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
22. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity
23. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor
24. Involvement of MACH, a novel MORT1/FADD-interacting protease in Fas/APO-1 and TNF-receptor-induced cell death
25. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex (DISC)
26. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain
27. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor-induced apoptosis
28. Viral-FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
29. Inhibition of death receptor signals by cellular FLIP
30. The role of c-FLIP in modulation of CD95-induced apoptosis
31. CASH, a novel caspase homologue with death effector domains
32. Casper is a FADD- and caspase-related inducer of apoptosis
33. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis
34. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis
35. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD95-induced apoptosis
36. Cell cycle-dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis
37. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
38. Relationship of TNF-related apoptosis-related ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
39. Metabolic inhibitors sensitize CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression
40. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways
41. Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD)
42. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP
43. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer
44. Synthesis of procaspases-3 and -7 during apoptosis in prostate cancer cells
45. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation
46. Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis
47. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b
48. Two CD95 (APO-1/Fas) signaling pathways
49. Establishment of human prostate xenografts in nude mice and response to 9-nitrocamptothecin in vivo and in vitro does not correlate with expression of various regulating proteins
50. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and taxol-induced growth arrest
51. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-co-stimulated human T cells
52. Pro-caspase-3 is a major physiologic target of caspase-8
53. Drug-induced apoptosis in hepatoma cells is mediated by CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53
54. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells
55. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors
56. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction
57. p28 Bap31, a Bcl-2/Bcl-XL, and procaspase-8-associated protein in the endoplasmic reticulum
58. Fas-dependent and -independent mechanisms of cell death following DNA damage in human colon carcinoma cells
59. Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis
60. Human DU145 prostate cancer cells over-expressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis
61. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells
62. Fas ligand is constitutively secreted by prostate cancer cells in vitro
63. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells
64. Inhibition of Fas death signals by FLIPs
65. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation
66. Mitogen-activated protein kinase kinase antagonized Fas-associated death domain protein-mediated apoptosis by induced FLICE-inhibitory protein expression
67. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors
68. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein
69. The inhibitor of death receptor signaling. FLICE-inhibitory protein defines a new class of tumor progression factors
70. Expression of c-FLIP1 and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cell: Inhibition by bisindolylmaleimide